Microbiome-Targeted Therapies for Primary Sclerosing Cholangitis
Seminars in Liver Disease · 06.11.2026
DOI: 10.1055/a-2983-7443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Liver Disease, online erschienen am 06.11.2026. Verfasst von Matthew Carson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Organ Pathobiology and Therapeutics Institute, University of Pittsburgh School of Medicine, Pennsylvania, United States, Pittsburgh. Die Arbeit nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Division of Diabetes, Endocrinology, and Metabolic Diseases (to K.N-B.), Burroughs Wellcome Fund Postdoctoral Enrichment Program Fellowship, American Liver Foundation Postdoctoral Fellowship.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is a rare, progressive cholestatic liver disease of the intrahepatic and extrahepatic bile ducts with poor prognosis. The only life-extending treatment for PSC is liver transplantation, with up to 25% of posttransplant patients developing recurrent disease, highlighting an extrahepatic influence on the disease. The gut–liver axis has been widely studied in the development and pathogenesis of PSC, with preclinical and clinical work demonstrating that targeting gut microbiota and its metabolites can elicit therapeutic effects against PSC. This review describes various microbiome-based therapeutics and their effectiveness in treating PSC, including antibiotics, probiotics, fecal microbiota transplantation, and bacteriophages. In conclusion, the use of microbiota-derived metabolites as potential therapeutics is also addressed.
Autor:innen und Institutionen
- Organ Pathobiology and Therapeutics Institute, University of Pittsburgh School of Medicine, Pennsylvania, United States, Pittsburgh.
- University of Pittsburgh School of Medicine, Department of Pharmacology and Chemical Biology, Pennsylvania, United States, Pittsburgh.
- Pittsburgh Liver Research Center, University of Pittsburgh and University of Pittsburgh Medical Center, Pennsylvania, United States, Pittsburgh.
ORCID-Profile: Vik Meadows
Förderung
- Division of Diabetes, Endocrinology, and Metabolic Diseases (to K.N-B.)
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Fellowship
- American Liver Foundation Postdoctoral Fellowship
- Pittsburgh Liver Institute Postdoc Pre-Pilot and Feasibility (3P&F) Award to M.C.
Zitieren
APA
Carson, M., Meadows, V., & Nejak-Bowen, K. (2026). Microbiome-Targeted Therapies for Primary Sclerosing Cholangitis. Seminars in Liver Disease. https://doi.org/10.1055/a-2983-7443
Vancouver
Carson M, Meadows V, Nejak-Bowen K. Microbiome-Targeted Therapies for Primary Sclerosing Cholangitis. Seminars in Liver Disease. 2026. doi:10.1055/a-2983-7443
BibTeX
@article{Carson2026,
author = {Carson, Matthew and Meadows, Vik and Nejak-Bowen, Kari},
title = {Microbiome-Targeted Therapies for Primary Sclerosing Cholangitis},
journal = {Seminars in Liver Disease},
year = {2026},
doi = {10.1055/a-2983-7443}
}
EUVIMED